Compare LUNG & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNG | ACET |
|---|---|---|
| Founded | 1995 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.2M | 69.6M |
| IPO Year | 2020 | 2017 |
| Metric | LUNG | ACET |
|---|---|---|
| Price | $1.28 | $6.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $5.38 | ★ $48.33 |
| AVG Volume (30 Days) | ★ 456.6K | 91.5K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $90,497,000.00 | N/A |
| Revenue This Year | $2.48 | N/A |
| Revenue Next Year | $18.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.01 | N/A |
| 52 Week Low | $1.13 | $0.45 |
| 52 Week High | $5.99 | $9.05 |
| Indicator | LUNG | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 42.88 |
| Support Level | $1.13 | $6.01 |
| Resistance Level | $1.93 | $8.34 |
| Average True Range (ATR) | 0.11 | 0.34 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 30.61 | 41.87 |
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.